A levoszimendán perioperatív alkalmazása a szívsebészetben: Magyar ajánlás

Translated title of the contribution: Perioperative use of levosimendan in cardiac surgery: Hungarian recommendation

Szudi László, Székely László, Sápi Erzsébet, Prodán Zsolt, Szolnoky Jeno, Csomós Ákos, Nyolczas Noémi, Paulovich Erzsébet, Németh Endre, Hartyánszky István, Zima Endre, Sax Balázs, Bertalan Andrea, Hejjel László, G. Bogáts, Babik Barna, Gombocz Károly, Szerafin Tamás, Koszta György, Molnár Andrea

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Low output syndrome significantly increases morbidity and mortality of cardiac surgery and lengthens the durations of intensive care unit and hospital stays. Its treatment by catecholamines can lead to undesirable systemic and cardiac complications. Levosimendan is a calcium sensitiser and adenosine triphosphate (ATP)-sensitive potassium channel (IK,ATP) opener agent. Due to these effects, it improves myocardium performance, does not influence adversely the balance between O2 supply and demand, and possesses cardioprotective and organ protective properties as well. Based on the scientific literature and experts' opinions, a European recommendation was published on the perioperative use of levosimendan in cardiac surgery in 2015. Along this line, and also taking into consideration cardiac surgeon, anaesthesiologist and cardiologist representatives of the seven Hungarian heart centres and the children heart centre, the Hungarian recommendation has been formulated that is based on two pillars: literature evidence and Hungarian expert opinions. The reviewed fields are: coronary and valvular surgery, assist device implantation, heart transplantation both in adult and pediatric cardiologic practice.

Original languageHungarian
Pages (from-to)870-877
Number of pages8
JournalOrvosi Hetilap
Volume159
Issue number22
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Expert Testimony
Thoracic Surgery
Intermediate-Conductance Calcium-Activated Potassium Channels
Adenosine Triphosphate
Literature
Heart Transplantation
Catecholamines
Intensive Care Units
Length of Stay
Myocardium
Pediatrics
Calcium
Morbidity
Equipment and Supplies
Mortality
simendan
Therapeutics
Cardiologists
Surgeons

ASJC Scopus subject areas

  • Medicine(all)

Cite this

László, S., László, S., Erzsébet, S., Zsolt, P., Jeno, S., Ákos, C., ... Andrea, M. (2018). A levoszimendán perioperatív alkalmazása a szívsebészetben: Magyar ajánlás. Orvosi Hetilap, 159(22), 870-877. https://doi.org/10.1556/650.2018.31083

A levoszimendán perioperatív alkalmazása a szívsebészetben : Magyar ajánlás. / László, Szudi; László, Székely; Erzsébet, Sápi; Zsolt, Prodán; Jeno, Szolnoky; Ákos, Csomós; Noémi, Nyolczas; Erzsébet, Paulovich; Endre, Németh; István, Hartyánszky; Endre, Zima; Balázs, Sax; Andrea, Bertalan; László, Hejjel; Bogáts, G.; Barna, Babik; Károly, Gombocz; Tamás, Szerafin; György, Koszta; Andrea, Molnár.

In: Orvosi Hetilap, Vol. 159, No. 22, 01.06.2018, p. 870-877.

Research output: Contribution to journalArticle

László, S, László, S, Erzsébet, S, Zsolt, P, Jeno, S, Ákos, C, Noémi, N, Erzsébet, P, Endre, N, István, H, Endre, Z, Balázs, S, Andrea, B, László, H, Bogáts, G, Barna, B, Károly, G, Tamás, S, György, K & Andrea, M 2018, 'A levoszimendán perioperatív alkalmazása a szívsebészetben: Magyar ajánlás', Orvosi Hetilap, vol. 159, no. 22, pp. 870-877. https://doi.org/10.1556/650.2018.31083
László S, László S, Erzsébet S, Zsolt P, Jeno S, Ákos C et al. A levoszimendán perioperatív alkalmazása a szívsebészetben: Magyar ajánlás. Orvosi Hetilap. 2018 Jun 1;159(22):870-877. https://doi.org/10.1556/650.2018.31083
László, Szudi ; László, Székely ; Erzsébet, Sápi ; Zsolt, Prodán ; Jeno, Szolnoky ; Ákos, Csomós ; Noémi, Nyolczas ; Erzsébet, Paulovich ; Endre, Németh ; István, Hartyánszky ; Endre, Zima ; Balázs, Sax ; Andrea, Bertalan ; László, Hejjel ; Bogáts, G. ; Barna, Babik ; Károly, Gombocz ; Tamás, Szerafin ; György, Koszta ; Andrea, Molnár. / A levoszimendán perioperatív alkalmazása a szívsebészetben : Magyar ajánlás. In: Orvosi Hetilap. 2018 ; Vol. 159, No. 22. pp. 870-877.
@article{872124b37b354cd187e2ce3cbf270223,
title = "A levoszimend{\'a}n perioperat{\'i}v alkalmaz{\'a}sa a sz{\'i}vseb{\'e}szetben: Magyar aj{\'a}nl{\'a}s",
abstract = "Low output syndrome significantly increases morbidity and mortality of cardiac surgery and lengthens the durations of intensive care unit and hospital stays. Its treatment by catecholamines can lead to undesirable systemic and cardiac complications. Levosimendan is a calcium sensitiser and adenosine triphosphate (ATP)-sensitive potassium channel (IK,ATP) opener agent. Due to these effects, it improves myocardium performance, does not influence adversely the balance between O2 supply and demand, and possesses cardioprotective and organ protective properties as well. Based on the scientific literature and experts' opinions, a European recommendation was published on the perioperative use of levosimendan in cardiac surgery in 2015. Along this line, and also taking into consideration cardiac surgeon, anaesthesiologist and cardiologist representatives of the seven Hungarian heart centres and the children heart centre, the Hungarian recommendation has been formulated that is based on two pillars: literature evidence and Hungarian expert opinions. The reviewed fields are: coronary and valvular surgery, assist device implantation, heart transplantation both in adult and pediatric cardiologic practice.",
keywords = "Cardiac surgery, Cardioprotective effect, Levosimendan, Low output syndrome",
author = "Szudi L{\'a}szl{\'o} and Sz{\'e}kely L{\'a}szl{\'o} and S{\'a}pi Erzs{\'e}bet and Prod{\'a}n Zsolt and Szolnoky Jeno and Csom{\'o}s {\'A}kos and Nyolczas No{\'e}mi and Paulovich Erzs{\'e}bet and N{\'e}meth Endre and Harty{\'a}nszky Istv{\'a}n and Zima Endre and Sax Bal{\'a}zs and Bertalan Andrea and Hejjel L{\'a}szl{\'o} and G. Bog{\'a}ts and Babik Barna and Gombocz K{\'a}roly and Szerafin Tam{\'a}s and Koszta Gy{\"o}rgy and Moln{\'a}r Andrea",
year = "2018",
month = "6",
day = "1",
doi = "10.1556/650.2018.31083",
language = "Hungarian",
volume = "159",
pages = "870--877",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "22",

}

TY - JOUR

T1 - A levoszimendán perioperatív alkalmazása a szívsebészetben

T2 - Magyar ajánlás

AU - László, Szudi

AU - László, Székely

AU - Erzsébet, Sápi

AU - Zsolt, Prodán

AU - Jeno, Szolnoky

AU - Ákos, Csomós

AU - Noémi, Nyolczas

AU - Erzsébet, Paulovich

AU - Endre, Németh

AU - István, Hartyánszky

AU - Endre, Zima

AU - Balázs, Sax

AU - Andrea, Bertalan

AU - László, Hejjel

AU - Bogáts, G.

AU - Barna, Babik

AU - Károly, Gombocz

AU - Tamás, Szerafin

AU - György, Koszta

AU - Andrea, Molnár

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Low output syndrome significantly increases morbidity and mortality of cardiac surgery and lengthens the durations of intensive care unit and hospital stays. Its treatment by catecholamines can lead to undesirable systemic and cardiac complications. Levosimendan is a calcium sensitiser and adenosine triphosphate (ATP)-sensitive potassium channel (IK,ATP) opener agent. Due to these effects, it improves myocardium performance, does not influence adversely the balance between O2 supply and demand, and possesses cardioprotective and organ protective properties as well. Based on the scientific literature and experts' opinions, a European recommendation was published on the perioperative use of levosimendan in cardiac surgery in 2015. Along this line, and also taking into consideration cardiac surgeon, anaesthesiologist and cardiologist representatives of the seven Hungarian heart centres and the children heart centre, the Hungarian recommendation has been formulated that is based on two pillars: literature evidence and Hungarian expert opinions. The reviewed fields are: coronary and valvular surgery, assist device implantation, heart transplantation both in adult and pediatric cardiologic practice.

AB - Low output syndrome significantly increases morbidity and mortality of cardiac surgery and lengthens the durations of intensive care unit and hospital stays. Its treatment by catecholamines can lead to undesirable systemic and cardiac complications. Levosimendan is a calcium sensitiser and adenosine triphosphate (ATP)-sensitive potassium channel (IK,ATP) opener agent. Due to these effects, it improves myocardium performance, does not influence adversely the balance between O2 supply and demand, and possesses cardioprotective and organ protective properties as well. Based on the scientific literature and experts' opinions, a European recommendation was published on the perioperative use of levosimendan in cardiac surgery in 2015. Along this line, and also taking into consideration cardiac surgeon, anaesthesiologist and cardiologist representatives of the seven Hungarian heart centres and the children heart centre, the Hungarian recommendation has been formulated that is based on two pillars: literature evidence and Hungarian expert opinions. The reviewed fields are: coronary and valvular surgery, assist device implantation, heart transplantation both in adult and pediatric cardiologic practice.

KW - Cardiac surgery

KW - Cardioprotective effect

KW - Levosimendan

KW - Low output syndrome

UR - http://www.scopus.com/inward/record.url?scp=85047872444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047872444&partnerID=8YFLogxK

U2 - 10.1556/650.2018.31083

DO - 10.1556/650.2018.31083

M3 - Article

C2 - 29806474

AN - SCOPUS:85047872444

VL - 159

SP - 870

EP - 877

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 22

ER -